Director/Senior Director, Innovation Licensing & Alliances (Business Development)

Organization
Nanostring Technologies
Job Location
Seattle, WA
Salary
DOE and level-Competitive comp
Benefits

ESPP, Stock Options, Matching 401K, PTO, and more...

Job Description

Position Summary:

NanoString is highly interested in collaborating with leading academic / research institutions and life science and biopharmaceutical partners to build a differentiated and sustainable platform and high information content applications, based on state-of-the-art genomic, proteomic and multi-omic technologies (at the RNA, protein and DNA levels). Reporting to the Senior VP of Corporate and Business Development and as a key member of the Corporate and Business Development team, the Director/Senior Director, Innovation Licensing & Alliances will be the primary business development lead to identify, evaluate, pursue, transact and implement cutting-edge innovation & technology to enable our Corporate and R&D Roadmaps. This position will be at the forefront of enabling key collaborations and accessing critical technology; and will work hand-in-hand with R&D, Commercial and other cross-functional teams including Legal, Finance and Operations to drive these initiatives forward.

Key Responsibilities:

Drive business development / transactional processes to access best-in-class innovation & alliances related to 1) new technologies to enhance and expand the nCounter® Analysis System platform, 2) new applications and content to provide high value, multi-dimensional genetic and proteomic information 3) investigator-driven research to generate new data and publications and 4) novel alliances with academia, governmental agencies, foundations and industrial partners. Specific activities include:
•Discover and prioritize potential opportunities by actively prospecting, collaborating with cross-functional partners and leveraging your network.
•Conduct robust analysis and due diligence to uncover the highest potential opportunities and de-risk decision making.
•Lead deal transaction / negotiation processes that meet strategic, technical and financial goals.
•Partner with R&D, Commercial and other cross-functional teams to accelerate deal making process and implementation.
•Gain internal and external support for the transaction.
•Support the integration and implementation of the technology or collaboration into NanoString.
•As part of a core team, ensure that the R&D roadmap and corporate strategy reflect current thinking and insight to build upon NanoString’s competitive advantage.
•Offer in-depth, multi-faceted knowledge and insight spanning the technology competitive landscape (including genomic and proteomic detection technologies), cancer biology (solid tumors, hematology and/or immune-oncology) and diagnostic/drug development.
•Identify, develop and maintain “peer-to-peer” scientific and business relationships with academia, governmental agencies, foundations, industrial partners and other stakeholders.
•Key member of the Corporate & Business Development team to ensure individual and departmental goals are achieved by providing leadership, company advocacy, team support and driving other key initiatives.

Requirements

*Must be willing and able to relocate to Seattle, WA HQ*

•PhD and/or MS degree in molecular biology, biochemistry, pharmacology, engineering or equivalent is required; in addition MBA desirable.
•Strong deal sheet highlighting track record of driving complex transactions from inception to execution including valuation, diligence, deal engineering, leading negotiations and execution.
•A solid reputation, network and relationships (scientific and business) within academia, life science & biopharmaceutical companies and other stakeholders worldwide.
•Deep understanding and command of cutting-edge technologies & innovation, oncology (including solid tumors, hematological and/or immuno-oncology), personalized medicine, molecular diagnostics and drug development.
•A strategic thinker with outstanding business instincts who can help chart the course and translate into actionable, value-creating results for the company.
•Excellent analytical and organizational skills with the ability to make sound business judgments.
•Extensive travel.
•Energetic, resourceful self-starter with high integrity and the ability to work effectively in a dynamic, collaborative environment.
•Strong passion to deliver technologies and collaborations capable of advancing Translational Research, ultimately benefiting patients through their diagnostic and therapeutic application.

About Our Organization

NanoString Technologies (NASDAQ:“NSTG”) provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 450 peer-reviewed publications, has also now been applied to diagnostic use as the nCounter Dx Analysis System. The company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity, reproducibility and precision. The company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna™ Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic kit to be marketed through the company's diagnostics business. Leveraging the company’s innovative platform and proven development, regulatory and commercial expertise , NanoString has established a companion diagnostics capability to enable biopharmaceuticals partners to translate biomarker discoveries into clinically-relevant diagnostics, helping to bring the right therapy to the right patient at the right time.

New study finds bias against female lecturers among student course evaluations, the Economist reports.

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.